Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Phase IV Clinical Development of Sinuforte (Nasodren) Nasal Spray More
The first topical protease inhibitor with antibacterial properties discovered and patented by Vitro-Bio. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jan 2011 - 124 pages - $1,740
Jun 2009 - 110 pages - $1,040
Jun 2008 - 175 pages - $3,835
Jan 2007 - 126 pages - $2,495
Nov 2010 - 428 pages - $2,695
Dec 2009 - 84 pages - $7,600
Apr 2010 - 510 pages - $2,695
Oct 2011 - 92 pages - $3,835
Jun 2009 - 472 pages - $3,140
Nov 2010 - 185 pages - $1,495
Your selection
Browse By
- Industry sector
- Intravesical
- Nasal
- Nasal topical
- Ophthalmic
- Oral liquid
- Oral solid
- Otic
- Parenteral
- Pulmonary
- Rectal
- Systemic
- Topical
- Vaginal
- Therapeutic target
- Aphthous ulcers
- Dental disorder (other)
- Gingivitis
- Gum disease
- Herpes simplex virus type 1 (oral)
- Mouth disorder (other)
- Mucositis oral
- Mucositis, Radiation-induced
- Periodontal disease
- Tooth decay
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us